SLS SELLAS Life Sciences Group, Inc. - Common Stock
NASDAQ · Biotechnology · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 11, 2026SLS Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
SLS Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
| Data ex-dividendo | Split | Tipo |
|---|---|---|
| 08 Novembre 2019 | 1-for-50 | Inverso |
| 02 Gennaio 2018 | 1-for-30 | Inverso |
| 14 Novembre 2016 | 1-for-20 | Inverso |
Informazioni su SELLAS Life Sciences Group, Inc. - Common Stock Panoramica della società da Wikipedia
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigating their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | SLS | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E | -55.6media 5 anni ≈-4.6 | ≈-4.6 | · | · | |
| P/B (MRQ) | 17.2media 5 anni ≈5.3 | ≈5.3 | 4.4 | Sopravvalutato | |
| Price / Cash Flow (Prezzo / Flusso di cassa) | -75.0media 5 anni ≈-5.8 | ≈-5.8 | · | · | |
| Price / Tangible Book (Prezzo / Valore contabile tangibile) | 30.9media 5 anni ≈10.1 | ≈10.1 | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | SLS | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| ROA | -54.9%media 5 anni ≈-160.6% | ≈-160.6% | -40.3% | Debole | |
| ROE | -55.4%media 5 anni ≈-45.6% | ≈-45.6% | -50.3% | Debole | |
| ROIC | -39.9%media 5 anni ≈-177.1% | ≈-177.1% | -39.9% | In linea |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | SLS | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Rapporto corrente (MRQ) | 18.8media 5 anni ≈3.7 | ≈3.7 | 14.8 | Liquidità elevata | |
| Quick Ratio | 10.2media 5 anni ≈3.5 | ≈3.5 | 8.7 | Liquidità elevata |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Dati fondamentali insufficienti per calcolare questo gruppo di rapporti.
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
| Metrica | Tendenza 5 anni | SLS | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Revenue / Employee (Ricavi / Dipendente) | ≈$0.00 | · | · | · |
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 10, 2026 | $-0.05 | $-0.05 | -9.9% |
| 31 Marzo 2026 | Mag 11, 2026 | $-0.05 | $-0.04 | -23.8% |
| 31 Dicembre 2025 | $-0.05 | $-0.07 | 23.9% | |
| 30 Settembre 2025 | $-0.06 | $-0.07 | 10.0% | |
| 30 Giugno 2025 | $-0.07 | $-0.08 | 15.9% | |
| 31 Marzo 2025 | $-0.07 | $-0.11 | 34.0% | |
| 31 Dicembre 2024 | $-0.08 | $-0.11 | 26.2% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
Efficienza
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.46 | $0.13 | $-0.25 | $0.23 | $1.28 | $1.96 | $1.20 | · | $0.36 | $1.89 | · | · | |
| Revenue / Share | · | · | $0.00 | $0.05 | $0.49 | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.26 | $-0.58 | $-1.13 | $-1.23 | $-1.68 | · | · | · | · | · | · | · | |
| Cash / Share | $0.47 | $0.19 | $0.08 | $0.82 | $1.34 | $2.48 | $1.43 | · | $0.40 | $1.19 | · | · | |
| EPS (TTM) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · |
Tassi di Crescita
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | · | 108,396,260 | 98,558,567 | 87,760,320 | · | 68,254,021 | 57,630,506 | 44,812,996 | · | 28,355,427 | 28,347,920 | 23,547,562 | · | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | · | 108,396,260 | 98,558,567 | 87,760,320 | · | 68,254,021 | 57,630,506 | 44,812,996 | · | 28,355,427 | 28,347,920 | 23,547,562 | · | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
Efficienza
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.68 | $0.59 | · | $0.36 | $0.26 | $0.31 | · | $0.25 | $0.05 | $0.17 | · | $-0.13 | $0.17 | $0.46 | · | $0.61 | |
| Revenue / Share | · | · | · | · | · | · | · | · | · | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | |
| Cash Flow / Share | · | $-0.05 | · | · | · | $-0.10 | · | · | · | $-0.24 | · | · | · | $-0.52 | · | · | |
| Cash / Share | $0.69 | $0.59 | · | $0.35 | $0.25 | $0.31 | · | $0.33 | $0.16 | $0.33 | · | $0.14 | $0.49 | $0.84 | · | $1.04 | |
| EPS (TTM) | $-0.21 | $-0.23 | · | $-0.26 | $-0.30 | $-0.36 | · | $-0.67 | $-0.90 | $-1.08 | · | $-1.44 | $-1.45 | $-1.55 | · | $-2.23 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $1M | |
| Net Income TTM | $-32M | $-29M | · | $-26M | $-26M | $-27M | · | $-32M | $-34M | $-36M | · | $-38M | $-36M | $-36M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -70.3 | -18.4 | · | -6.2 | -7.3 | -3.0 | · | -1.9 | -1.3 | -0.9 | · | -1.1 | -1.1 | -0.9 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.4% | -5.4% | · | -16.2% | -13.7% | -33.3% | · | -53.6% | -75.6% | -106.9% | · | -87.8% | -92.4% | -108.4% | · | -110.4% |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ricavi | · | · | $0 | $1M | $8M |
| Margine Operativo % | · | · | · | -4195.0% | -332.8% |
| Utile netto | $-27M | $-31M | $-37M | $-41M | $-21M |
| EPS Diluito | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rapporto corrente | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
Dati fondamentali insufficienti per creare questo bilancio al momento.
Proprietari istituzionali (13F) 234 filer · $1.5B totale · Aggiornato al 30 Settembre 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 85 (+18 vs trimestre precedente) | 19 (+4 vs trimestre precedente) | 84 (+25 vs trimestre precedente) | 31 (+8 vs trimestre precedente) | +33.3M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $222.437.657 | 15.070.302 | 14,45% | Azioni |
| STATE STREET CORP | $191.829.196 | 12.996.558 | 12,47% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $121.417.310 | 8.226.105 | 7,89% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105.640.272 | 7.157.200 | 6,86% | Opzione Call |
| GEODE CAPITAL MANAGEMENT, LLC | $72.107.010 | 4.884.175 | 4,69% | Azioni |
| Anson Funds Management LP | $66.420.000 | 4.500.000 | 4,32% | Azioni |
| CITADEL ADVISORS LLC | $64.157.292 | 4.346.700 | 4,17% | Opzione Call |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61.832.592 | 4.189.200 | 4,02% | Opzione Put |
| CITADEL ADVISORS LLC | $33.333.984 | 2.258.400 | 2,17% | Opzione Put |
| VANGUARD GROUP INC | $31.922.098 | 8.467.400 | 2,07% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31.897.821 | 2.161.099 | 2,07% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30.266.812 | 2.050.597 | 1,97% | Azioni |
| JONES FINANCIAL COMPANIES LLLP | $28.553.511 | 2.304.561 | 1,86% | Azioni |
| Anson Funds Management LP | $27.245.484 | 1.845.900 | 1,77% | Opzione Put |
| NORTHERN TRUST CORP | $23.910.138 | 1.619.928 | 1,55% | Azioni |
| PERCEPTIVE ADVISORS LLC | $22.140.000 | 1.500.000 | 1,44% | Opzione Put |
| VANGUARD FIDUCIARY TRUST CO | $19.707.050 | 1.335.166 | 1,28% | Azioni |
| UBS Group AG | $18.490.693 | 1.252.757 | 1,20% | Azioni |
| MORGAN STANLEY | $18.247.211 | 1.236.261 | 1,19% | Azioni |
| Sio Capital Management, LLC | $18.165.132 | 1.230.700 | 1,18% | Opzione Put |
| BNP PARIBAS FINANCIAL MARKETS | $15.823.045 | 1.072.022 | 1,03% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $15.424.200 | 10.450 | 1,00% | Opzione Put |
| MILLENNIUM MANAGEMENT LLC | $13.372.560 | 906.000 | 0,87% | Opzione Put |
| BARCLAYS PLC | $11.831.616 | 801.600 | 0,77% | Opzione Put |
| Anson Funds Management LP | $11.808.000 | 800.000 | 0,77% | Opzione Call |
| BANK OF AMERICA CORP /DE/ | $11.630.128 | 787.949 | 0,76% | Azioni |
| JANE STREET GROUP, LLC | $11.058.192 | 749.200 | 0,72% | Opzione Call |
| WELLINGTON MANAGEMENT GROUP LLP | $8.816.282 | 597.309 | 0,57% | Azioni |
| GOLDMAN SACHS GROUP INC | $8.635.117 | 585.035 | 0,56% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8.339.518 | 565.008 | 0,54% | Azioni |
| Bank of New York Mellon Corp | $7.823.173 | 530.025 | 0,51% | Azioni |
| JANE STREET GROUP, LLC | $7.504.412 | 508.429 | 0,49% | Azioni |
| Balyasny Asset Management L.P. | $7.380.000 | 500.000 | 0,48% | Opzione Put |
| LMR Partners LLP | $6.642.000 | 450.000 | 0,43% | Opzione Put |
| NOMURA HOLDINGS INC | $6.273.000 | 425.000 | 0,41% | Opzione Call |
| Nuveen, LLC | $6.180.440 | 418.729 | 0,40% | Azioni |
| DIADEMA PARTNERS LP | $5.904.000 | 400.000 | 0,38% | Opzione Call |
| Invesco Ltd. | $5.540.049 | 375.342 | 0,36% | Azioni |
| Swiss National Bank | $5.319.504 | 360.400 | 0,35% | Azioni |
| XTX Topco Ltd | $5.300.168 | 359.090 | 0,34% | Azioni |
| Ikarian Capital, LLC | $5.235.372 | 354.700 | 0,34% | Opzione Put |
| WELLS FARGO & COMPANY/MN | $4.853.368 | 328.819 | 0,32% | Azioni |
| CITIGROUP INC | $4.820.483 | 326.591 | 0,31% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $4.580.973 | 310.364 | 0,30% | Azioni |
| DAGCO, INC. | $4.351.740 | 1.028.780 | 0,28% | Azioni |
| Everhart Financial Group, Inc. | $4.251.146 | 288.018 | 0,28% | Azioni |
| Rafferty Asset Management, LLC | $3.540.806 | 239.892 | 0,23% | Azioni |
| RHUMBLINE ADVISERS | $3.400.726 | 230.402 | 0,22% | Azioni |
| Walleye Capital LLC | $3.377.088 | 228.800 | 0,22% | Opzione Put |
| TUDOR INVESTMENT CORP ET AL | $3.087.792 | 209.200 | 0,20% | Opzione Put |
Attivisti e proprietari del 5%+ 2 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 depositi | 10 Ottobre 2018 | · | Deposito iniziale | · | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | 08 Gennaio 2018 | · | Deposito iniziale | M&A / vendita | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 43 insider · 17 dirigenti · 9 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | 16 Giugno 2026 A | 1.759.183 | 0 | 0 | $0 |
| Mark W. Schwartz | President & CEO | 01 Luglio 2016 J | 439.978 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | 15 Marzo 2011 A | 92.994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | 07 Gennaio 2026 A | 554.327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | 20 Aprile 2018 A | · | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | 13 Aprile 2011 A | 379.294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | 15 Gennaio 2009 A | · | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | 07 Gennaio 2026 A | 557.805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | 22 Gennaio 2024 A | 40.918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | 22 Gennaio 2024 A | 117.225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | 14 Marzo 2019 A | · | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | 13 Marzo 2018 A | · | 0 | 0 | $0 |
| Kwang Lee | Principal Accounting Officer | 07 Dicembre 2011 P | 5.000 | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | 15 Marzo 2011 A | 14.065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | 15 Marzo 2011 A | 41.083 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | 15 Aprile 2010 A | 5.750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | 31 Marzo 2010 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | Direttore | 07 Gennaio 2026 A | 154.400 | 1 | 0 | $100.806 |
| John Varian | Direttore | 07 Gennaio 2026 A | 72.900 | 0 | 0 | $0 |
| Jane Wasman | Direttore | 07 Gennaio 2026 A | 92.900 | 0 | 0 | $0 |
| David A Scheinberg | Direttore | 07 Gennaio 2026 A | 73.082 | 0 | 0 | $0 |
| Robert L Van Nostrand | Direttore | 07 Gennaio 2026 A | 82.900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | Direttore | 14 Marzo 2019 A | · | 0 | 0 | $0 |
| Fabio Lopez | Direttore | 12 Giugno 2018 A | · | 0 | 0 | $0 |
| Irving M. Einhorn | · | 10 Ottobre 2017 A | 34.690 | 0 | 0 | $0 |
| William Ashton | · | 10 Ottobre 2017 A | 38.154 | 0 | 0 | $0 |
| Richard Chin | · | 10 Ottobre 2017 A | 31.339 | 0 | 0 | $0 |
| Rudolph Nisi | · | 10 Ottobre 2017 A | 42.918 | 0 | 0 | $0 |
| Sanford Hillsberg | · | 10 Ottobre 2017 A | 56.950 | 0 | 0 | $0 |
| Mary Ann Gray | · | 10 Ottobre 2017 A | 39.167 | 0 | 0 | $0 |
| Stephen S Galliker | · | 10 Ottobre 2017 A | 36.039 | 0 | 0 | $0 |
| Thomas J Knapp | · | 06 Febbraio 2017 A | · | 0 | 0 | $0 |
| Bijan Nejadnik | · | 17 Gennaio 2017 A | 8.503 | 0 | 0 | $0 |
| Ryan Dunlap | · | 01 Giugno 2016 M | 18.702 | 0 | 0 | $0 |
| Steven A Kriegsman | · | 19 Giugno 2015 A | 5.000 | 0 | 0 | $0 |
| Margaret Kivinski | · | 16 Gennaio 2015 A | · | 0 | 0 | $0 |
| Brian L Hamilton | · | 30 Giugno 2014 J | 2.461 | 0 | 0 | $0 |
| Mark J Ahn | · | 30 Giugno 2014 A | 116.225 | 0 | 0 | $0 |
| Rosemary Mazanet | · | 29 Gennaio 2013 A | · | 0 | 0 | $0 |
| Anastasia Khvorova | · | 24 Settembre 2011 A | 137.482 | 0 | 0 | $0 |
| Pamela Pavco | · | 24 Settembre 2011 A | 44.940 | 0 | 0 | $0 |
| CYTRX CORP | · | 29 Dicembre 2010 S | 0 | 0 | 0 | $0 |
| Tod Woolf | · | 15 Gennaio 2009 A | · | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 25 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,86% | 39.695 NS | 31 Luglio 2026 | N-PORT |
| IWC · iShares Trust | 0,60% | 640.712 SH | 11 Settembre 2026 | Giornaliero |
| LABU · Direxion Shares ETF Trust | 0,59% | 293.250 NS | 31 Luglio 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,23% | 316.525 SH | 19 Agosto 2026 | Giornaliero |
| ICOP · iShares Trust | 0,21% | 131.527 SH | 11 Settembre 2026 | Giornaliero |
| IWO · iShares Trust | 0,17% | 1.775.566 SH | 11 Settembre 2026 | Giornaliero |
| PWS · Pacer Funds Trust | 0,17% | 4.006 NS | 31 Luglio 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,16% | 202.339 SH | 19 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | 0,08% | 4.838.243 SH | 11 Settembre 2026 | Giornaliero |
| ISCG · iShares Trust | 0,08% | 57.697 SH | 11 Settembre 2026 | Giornaliero |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,08% | 1.086.285 SH | 19 Agosto 2026 | Giornaliero |
| RSSL · Global X Funds | 0,06% | 90.355 NS | 31 Luglio 2026 | N-PORT |
| ESML · iShares Trust | 0,05% | 105.699 SH | 11 Settembre 2026 | Giornaliero |
| PICK · iShares, Inc. | 0,05% | 147.515 SH | 11 Settembre 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,04% | 540.244 SH | 19 Agosto 2026 | Giornaliero |
| ISCF · iShares Trust | 0,04% | 30.200 SH | 11 Settembre 2026 | Giornaliero |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.134.285 SH | 19 Agosto 2026 | Giornaliero |
| WSML · iShares Trust | 0,03% | 17.066 SH | 11 Settembre 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 85.332 NS | 31 Luglio 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 273.788 SH | 11 Settembre 2026 | Giornaliero |
| IWV · iShares Trust | 0,00% | 44.399 SH | 11 Settembre 2026 | Giornaliero |
| IXUS · iShares Trust | 0,00% | 98.316 SH | 11 Settembre 2026 | Giornaliero |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5.908.560 SH | 19 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 15.706 SH | 19 Agosto 2026 | Giornaliero |
| ISCB · iShares Trust | · | 8.283 SH | 11 Settembre 2026 | Giornaliero |
SLS Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
Target Price a 12 Mesi
2 analisti · 2026-10-02Target medio $32.50 +176,8%
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | · | · | -55.4% | · |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | · |
| CLDX | $1.81B | -7.0 | -78.0% | -16748.0% | -43.8% | · |
| IRON | $3.01B | -13.2 | · | · | -31.3% | · |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | · |
| IMNM | $2.43B | -8.8 | -23.2% | -3060.0% | -47.0% | · |
| VRDN | $3.17B | -7.7 | 23359.9% | -483.6% | -55.4% | · |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | · |
| VERA | · | -10.9 | · | · | -55.9% | · |
| ADMA | $4.34B | 30.4 | 19.6% | 28.8% | 33.6% | 57.4% |
Ultime notizie Notizie recenti che menzionano questa società
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.